Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at Fareston til behandling af østrogen receptor positive tumorer svarer til tamoxifen hvad angår fordele og risici.
The Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits and risks of Fareston were comparable to those of tamoxifen in women with oestrogen-receptor-positive tumours.